Roth Capital Has Negative Outlook for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Analysts at Roth Capital reduced their FY2028 earnings per share estimates for Revelation Biosciences in a research report issued to clients and investors on Wednesday, December 4th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $2.03 per share for the year, down from their prior estimate of $2.06. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share.

Revelation Biosciences Price Performance

REVB opened at $0.44 on Friday. The company has a market capitalization of $1.89 million, a P/E ratio of -0.03 and a beta of 0.15. The firm’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.26. Revelation Biosciences has a fifty-two week low of $0.42 and a fifty-two week high of $25.26.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.